Isoptin (Verapamil Hydrochloride)

Verapamil hydrochloride blocks L‑type calcium channels in cardiac muscle, vascular smooth muscle, and the conduction system. This reduces calcium entry into cells, leading to decreased myocardial contractility, slowed atrioventricular nodal conduction, and dilation of peripheral blood vessels, which together produce its antihypertensive, anti‑anginal, and antiarrhythmic effects.

The specific dose of Isoptin is determined by the prescribing clinician based on the patient’s condition, response, and overall health status. Dosage may differ for oral versus intravenous administration and is adjusted to achieve therapeutic goals while minimizing adverse effects.

Safety data for verapamil hydrochloride in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate individual circumstances before prescribing Isoptin to pregnant or nursing patients.

To request Isoptin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Isoptin (verapamil) is a non‑dihydropyridine calcium channel blocker, distinguished by its pronounced effects on cardiac conduction and contractility. Compared with dihydropyridine agents such as amlodipine, verapamil more directly slows heart rate and AV‑node transmission, making it useful for arrhythmias, whereas dihydropyridines primarily cause vasodilation with minimal cardiac impact.

Isoptin should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the drug’s stability and potency throughout its shelf life.

Isoptin is available for oral administration as tablets and for intravenous infusion. The route, dosage form, and infusion rate are selected by the prescriber according to the clinical indication, patient tolerance, and therapeutic objectives.

Serious risks include marked bradycardia, severe hypotension, heart block, and rare cases of hepatotoxicity or allergic reactions. Patients should be monitored for signs of these events, especially during treatment initiation or dose adjustments.

Isoptin is contraindicated in patients with known hypersensitivity to verapamil, severe left ventricular dysfunction, advanced atrioventricular block without a pacemaker, and in those with acute myocardial infarction where its negative inotropic effect could be harmful.